NitroMed, manufacturer of BiDil, has received an offer from Deerfield Management, a private equity firm in December. Earlier today, Deerfield Management upped its offer for NitroMed.
BiDil was the first drug approved in an a racial sub-population. The drug got the nod back in 2005 for heart failure in African Americans.
Given the cheap valuations on Wall Street, private equity firms and big pharmas are going to continue gobbling up smaller biotech firms.
